Posted 5th December 2018 by Kieran Chambers
2018 will be remembered as a decisive year for immuno-oncology. In particular, Nobel Prize winners James Allison of MD Anderson Cancer Center in Houston, Texas, and Tasuku Honjo of Kyoto University in Japan lifted the field of immunotherapy to international recognition for those outside the scientific and medical communities. For the patient, these new alternatives to standard oncology therapies offer new hope for life-extending treatments using immunotherapy.
Human Genomic Evidence: Revolutionising the identification and prioritisation of targets for better medicines
Posted 17th October 2018 by Kieran Chambers
Nine out of 10 potential drugs that enter clinical trials never make it to the market. Failure often occurs because the biological target chosen is not well understood. However, it is hard to objectively select targets with a high chance of clinical success because the data required to predict efficacy and safety are complex, dispersed and incomplete. To address this challenge, Open Targets was founded in 2014 as a public-private partnership by GSK, EMBL-EBI and the Wellcome Sanger Institute. The consortium has grown since its launch, welcoming new partners Biogen in 2016, Takeda in 2017, and Celgene in 2018.
Posted 10th October 2018 by Kieran Chambers
This article was originally published by Technology Networks in August 2018 and is published here with permission.
John Baldoni currently heads up a drug discovery unit at GlaxoSmithKline. Since joining GSK in 1989, John has held numerous positions within the company and has led many significant cross-functional strategic initiatives. He has an impressive 37 years’ experience working within the biopharmaceutical industry.
The recently established Accelerating Therapeutics for Opportunities in Medicine consortium, was conceived by John, with a mission “to accelerate the development of more effective therapies for patients”. ATOM stemmed from the Cancer Moonshot, an initiative that aims to improve the availability of cancer therapies, enhance detection of cancer early on, and improve our ability to prevent cancer.
Posted 3rd October 2018 by Kieran Chambers
Digital innovation in healthcare promises much. But potential and realisation are two very different things.
Researchers at Stanford in the US, for example, have developed an AI algorithm designed to diagnose skin cancer. AI diagnosis was compared with that of 21 dermatologists and it matched the efficacy of its human counterparts. This has significant implications for patients, particularly those who find it difficult to access healthcare professionals. But the implications don’t stop there.
Posted 17th September 2018 by Kieran Chambers
Drug discovery and development is a complex process that requires integration of multiple data points, experiments and calculated risk/benefit assumptions. It is therefore only natural that virtualization and big data analytics are a natural fit for implementations, expected to demonstrate significant cost-effective gains for the betterment of society, providing access to effective and safe medications.
Big Data Analytics and Artificial Intelligence: 7 Design Principles to Empower Life Science Researchers
Posted 5th January 2018 by Laura Berry
Life sciences research is increasingly relying on big data analytics to drive scientific discovery. One of the contributing factors to this trend is the fact that researchers are confronted with a rapidly growing body of scientific literature and databases required to interpret experimental outcomes.
Posted 22nd December 2017 by Laura Berry
The traditional product pipeline, which information technology will compress and alter significantly in the life sciences in the coming years. Source: Wikimedia user MattBishop5 (CC BY-SA 3.0).
This article was originally published by Dassault Systèmes BIOVIA in October 2017, and is published here with permission.
Where can life science companies go operationally to maintain or create a competitive advantage? This question has been a constant in the industry since its inception, but recent advances in older technologies like Laboratory Information Management Systems (LIMS) and the appearance of promising newer technologies like the Internet of Things (IoT) have changed the nature of the answer. Which new technologies that are theoretically worthwhile have matured enough to be gracefully implemented operationally?